正海生物(300653) - 2023年7月31日投资者关系活动记录表

Financial Performance - In the first half of 2023, the company achieved total revenue of approximately 225 million CNY, a decrease of 2.99% compared to the same period last year [1] - The net profit attributable to shareholders was approximately 110 million CNY, an increase of 5.53% year-on-year [1] - The net profit after deducting non-recurring gains and losses was also about 110 million CNY, with a year-on-year growth of 6.04% [1] - Earnings per share reached 0.61 CNY, reflecting a growth of 5.17% [1] Product Sales - Sales revenue from oral repair membranes was approximately 106 million CNY, a decrease of 3.57% year-on-year [1] - Sales revenue from absorbable dura (spinal) patch products was 9.093 million CNY, an increase of 6.13% compared to the previous year [1] - The company expanded its marketing reach, with products listed in over 2,600 categories across 31 provinces, an increase of about 270 categories compared to the end of 2022 [1] Research and Development - The clinical trials for calcium silicate bio-ceramic bone repair materials have successfully completed nationwide enrollment, achieving significant progress [1] - The company is actively advancing the clinical trials for several products, including breast patches and uterine repair membranes, which are currently in the enrollment phase [2] Market Strategy - The company successfully participated in procurement projects for absorbable dura (spinal) patch products in Jiangsu and Liaoning provinces, with plans to actively engage in future procurement projects [2] - The demand for oral repair membranes has shown fluctuations, with significant impacts from external factors and market conditions, but there are signs of recovery in demand as of July 2023 [2] Other Business Aspects - The company has terminated its agency business for implant products due to the implementation of procurement policies, resulting in a decline in related revenue [3] - The transition of active biological bone products is expected to be completed within the year, with plans for official market launch next year [4] - The company is continuously improving its compensation and incentive mechanisms to attract and retain talent, with stock incentive plans being an integral part of its compensation system [5] - Revenue recognition follows a direct sales model and a distribution model, with income confirmed based on product usage records from hospitals and distributors [6]